Johnson & Johnson Might Be Tempted to Buy These 2 Device Makers

Like most everything else these days, medical technology stocks have reached their highest valuations in decades. But unlike some sectors—say, cannabis, that other kind of medical technology—med tech’s shares might stay aloft.

Analysts in many corners of the market are nervously assessing the heights their stocks have scaled. The software issues in the iShares North American Tech-Software exchange-traded fund (ticker: IGV) are up 29% this year, compared with 9% for the S&P 500.

The med-tech sector is the year’s next strongest gainer. It’s advanced 26%, as measured by the iShares U.S. Medical Devices ETF (IHI). In a recent meditation on med-tech valuations, the analysts at Canaccord Genuity Group attribute med tech’s outperformance to revenue growth, merger activity, and the defensive character of health-care stocks when economic expansions slow.

Hot performers among medical-device stocks this year include cardio device maker Boston Scientific( BSX) and robot surgery leader Intuitive Surgical (ISRG), each up 50%. Canaccord’s Jason Mills and Kyle Rose note that such large-cap med-tech stocks now trade at an average of 5.5 times 2019 sales, compared with a range of two-to-3.5-times over the past decade.

One reason med tech trades at a premium, they say, is its double-digit sales growth. Another reason is scarcity. Over the past 10 years, mergers have reduced the number of publicly traded med-tech outfits from more than 110 to 77. Canaccord thinks the group will maintain its premium.

Mergers among device makers will also probably continue. Wells Fargo analyst Larry Biegelsen speculates that Boston Scientific or its heart-valve rival, Edwards Lifesciences (EW), would make sense as an acquisition for Johnson & Johnson (JNJ). In a Sept. 16 note, the analyst observed that devices accounted for 41% of J&J’s total sales in 2012 but are expected to generate only 32% in 2019. Lately, he writes, J&J Chief Executive Alex Gorsky has called out the increasing innovation and friendlier regulation of devices, compared with some other products.

By Bill Alpert | Barron’s

Image Credit: Ron Antonelli/Bloomberg


About Peter Coffaro 668 Articles
A growth-driven and strategic executive, Peter Coffaro commands more than 20 years of progressive management success within the orthopedic industry. Recognized by and the World Journal of Orthopedics as one of the top medical sales influencers in the industry; he has 10 years of combined sales management experience and has held positions as a Director, General Manager, Distributor and Vice President. Peter has worked for some of the top orthopedic companies in the world - Zimmer, DePuy and Stryker. He is also the founder of OrthoFeed: a popular blog that covers digital orthopedic news and emerging medical technologies. Peter is a three-time Hall of Fame award winner at Johnson and Johnson and has an extensive background in organizational development, business development, sales management, digital marketing and professional education. Peter holds a B.S. degree in Biology from Northern Illinois University.

Be the first to comment

Leave a Reply

Your email address will not be published.


This site uses Akismet to reduce spam. Learn how your comment data is processed.